Thomas J Povsic, Serge Korjian, M Cecilia Bahit, Gerald Chi, Danielle Duffy, John H Alexander, Dragos Vinereanu, Pierluigi Tricoci, Sojaita Jenny Mears, Lawrence I Deckelbaum, Marc Bonaca, Paul M Ridker, Shaun G Goodman, Jan H Cornel, Basil S Lewis, Alexander Parkhomenko, Renato D Lopes, Philip Aylward, A Michael Lincoff, Mark Heise, Frank Sacks, Jose C Nicolau, Bela Merkely, Jaroslaw Trebacz, Peter Libby, Stephen J Nicholls, Stuart Pocock, Deepak L Bhatt, John Kastelein, Christophe Bode, Kenneth W Mahaffey, P Gabriel Steg, Michal Tendera, Kevin R Bainey, Robert A Harrington, Roxana Mehran, Daniel Duerschmied, Bronwyn A Kingwell, C Michael Gibson
BACKGROUND: The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. OBJECTIVES: This exploratory analysis evaluates the effect of CSL112 therapy on the incidence of CV death and recurrent MI. METHODS: The AEGIS-II trial was an international, multicenter, randomized, double-blind, placebo-controlled trial that randomized 18,219 high-risk acute MI patients to 4 weekly infusions of apoA-I (6g CSL112) or placebo...
March 25, 2024: Journal of the American College of Cardiology